Haemonetics (NYSE: HAE) reported Q1 EPS of $0.46, $0.05 better than the analyst estimate of $0.41. Revenue for the quarter came in at $196 million versus the consensus estimate of $198.27 million.

FISCAL 2021 GUIDANCE The Company did not issue fiscal 2021 guidance due to the continued uncertainty about the pace and timing of the COVID-19 pandemic and recovery. The Company is currently assessing potential scenarios for the macroeconomic impact of COVID-19 and the related effect on healthcare beyond the current quarter, informed by milestones and market indicators. As a result, the Company intends to issue guidance later in its fiscal year.

For earnings history and earnings-related data on Haemonetics (HAE) click here.